Development of pulmonary and cardiac sarcoidosis during etanercept therapy.
Department of Rheumatology, National Hospital Organization Yokohama Medical Center, Yokohama, Japan.
Rumiko
R
Miyagi
Haruko
H
Ideguchi
Takayoshi
T
Soga
Yasushi
Y
Yamakawa
Hisao
H
Otsuki
Hitoshi
H
Niino
Takeki
T
Shiina
Atsuhisa
A
Ueda
Yoshiaki
Y
Ishigatsubo
D000368:Aged; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D009202:Cardiomyopathies / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D000068800:Etanercept; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D011239:Prednisolone / Q000627:therapeutic use; D018124:Receptors, Tumor Necrosis Factor; D012307:Risk Factors; D012507:Sarcoidosis / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D017565:Sarcoidosis, Pulmonary / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D013997:Time Factors; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D018501:Antirheumatic Agents; D005938:Glucocorticoids; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D011239:Prednisolone; D000068800:Etanercept